Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pembrolizumab in Limited Stage Small Cell Lung Cancer
NCT06140407Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in small cell lung cancer (SCLC), sponsored by Vanderbilt-Ingram Cancer Center. Started Feb 2024; status: terminated.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06140407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140407.